

Treatment-Naive Genotype 1a Without Cirrhosis

| Recommended and alternative regimens listed by evidence level and alphabetically for: | | |
|--|----------|--------|
| Treatment-Naive Genotype 1a Patients Without Cirrhosis | | |
| RECOMMENDED | DURATION | RATING |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^a | 8 weeks | I, A |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | I, A |
| <hr/> | | |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are HIV-uninfected and whose HCV RNA level is <6 million IU/mL | 8 weeks | I, B |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
| ALTERNATIVE | DURATION | RATING |
| Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | 12 weeks | I, A |
| ^a Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. | | |

Last update: September 29, 2021

Treatment-Naive Genotype 1a With Compensated Cirrhosis

| Recommended regimens listed by evidence level and alphabetically for: | | |
|---|----------|--------|
| Treatment-Naive Genotype 1a Patients With Compensated Cirrhosis ^a | | |
| RECOMMENDED | DURATION | RATING |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | I, A |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b | 8 weeks | I, B |
| ^a For decompensated cirrhosis , please refer to the appropriate section. ^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. For patients with HIV/HCV coinfection, a treatment duration of 12 weeks is recommended. | | |

Recommended regimens listed by evidence level and alphabetically for:


Treatment-Naive Genotype 1a Patients With Compensated Cirrhosis^a

Last update: September 29, 2021

Treatment-Naive Genotype 1b Without Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Patients Genotype 1b Without Cirrhosis


| RECOMMENDED | DURATION | RATING  |
|--|-----------------------|--|
| Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | 12 weeks ^a | I, A |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b | 8 weeks | I, A |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | I, A |
| <hr/> | | |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are HIV-uninfected and whose HCV RNA level is <6 million IU/mL | 8 weeks ^c | I, B |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
| <p>^a An 8-week regimen can be considered in those with genotype 1b infection and mild fibrosis (see text for details). ^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. ^c For HIV/HCV coinfecting patients, a treatment duration of 12 weeks is recommended.</p> | | |

Last update: September 29, 2021

Treatment-Naive Genotype 1b With Compensated Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 1b Patients With Compensated Cirrhosis^a

| RECOMMENDED | DURATION | RATING  |
|---|----------------------|--|
| Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | 12 weeks | I, A |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | I, A |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b | 8 weeks ^c | I, B |

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

^c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended.

Last update: September 29, 2021

Treatment-Naive Genotype 2 Without Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 2 Patients Without Cirrhosis

| RECOMMENDED | DURATION | RATING  |
|---|----------|--|
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^a | 8 weeks | I, A |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |


^a Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: September 29, 2021

Treatment-Naive Genotype 2 With Compensated Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 2 Patients With Compensated Cirrhosis^a

| RECOMMENDED | DURATION | RATING  |
|---|----------------------|--|
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b | 8 weeks ^c | I, B |

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.


^c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended.

Last update: September 29, 2021

Treatment-Naive Genotype 3 Without Cirrhosis

Recommended regimens listed alphabetically for:

Treatment-Naive Genotype 3 Patients Without Cirrhosis

| RECOMMENDED | DURATION | RATING  |
|---|----------|--|
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^a | 8 weeks | I, A |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |



^a Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: September 29, 2021

Treatment-Naive Genotype 3 With Compensated Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 3 Patients With Compensated Cirrhosis^a

| RECOMMENDED | DURATION | RATING  |
|---|----------------------|--|
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b | 8 weeks ^c | I, B |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for patients without baseline NS5A RAS Y93H for velpatasvir | 12 weeks | I, A |
| ALTERNATIVE | DURATION | RATING  |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) with weight-based ribavirin for patients with baseline NS5A RAS Y93H for velpatasvir | 12 weeks | IIa, A |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) for patients with baseline NS5A RAS Y93H for velpatasvir | 12 weeks | IIa, B |

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.


^c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended.

Last update: September 29, 2021

Treatment-Naive Genotype 4 Without Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 4 Patients Without Cirrhosis

| RECOMMENDED | DURATION | RATING  |
|---|----------|--|
| Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | 12 weeks | I, A |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^a | 8 weeks | I, A |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) ^b | 12 weeks | I, A |

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 4 Patients Without Cirrhosis

| | | |
|--|----------|------|
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
|--|----------|------|

^a Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.


^b An 8-week regimen can be considered in patients with favorable baseline characteristics (ie, no cirrhosis, HCV RNA <6 million IU/mL, and absence of genotype 4r).

Last update: September 29, 2021

Treatment-Naive Genotype 4 With Compensated Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 4 Patients With Compensated Cirrhosis^a

| RECOMMENDED | DURATION | RATING  |
|---|----------------------|--|
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b | 8 weeks ^c | I, B |
| Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | 12 weeks | IIa, B |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | IIa, B |

^a For [decompensated cirrhosis](#), please refer to the appropriate section.


^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.


^c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended.

Last update: September 29, 2021

Treatment-Naive Genotype 5 or 6

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 5 or 6 Patients With and Without Compensated Cirrhosis^a 

| RECOMMENDED | DURATION | RATING  |
|---|----------------------|--|
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b | 8 weeks ^c | I, A ^d |
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, B |
| Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) ^e | 12 weeks | Ila, B |

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

^c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended.

^d For compensated cirrhosis, rating is I, B.

^e Not recommended for genotype 6e if subtype is known.

Last update: September 29, 2021